Logo

NPB

Northpointe Bancshares, Inc.

NPB

Northpointe Bancshares, Inc. • NYSE
$17.44 ▲ 0.29% (+0.05)
Market Cap $260.57 M
52w High $18.86
52w Low $11.43
Dividend Yield 0.10%
P/E 9.64
Volume 73.56K
Outstanding Shares 14.94M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $56.525M ▲ $-1.439M ▼ $22.174M ▲ 39.229% ▲ $1.36 ▲ $93.011M ▲
Q2-2025 $0 $7.114M ▲ $-5.504M ▼ 0% $-0.069 ▲ $-7.114M ▼
Q1-2025 $0 $5.266M ▼ $-3.15M ▲ 0% $-0.28 ▼ $-5.266M ▲
Q4-2024 $0 $13.371M ▲ $-9.062M ▲ 0% $-0.11 ▲ $-12.098M ▼
Q3-2024 $0 $12.412M $-20.491M 0% $-0.25 $-6.422M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $0 ▼ $6.84B ▲ $6.216B ▲ $623.525M ▲
Q2-2025 $165.614M ▼ $206.708M ▼ $9.975M ▼ $196.733M ▼
Q1-2025 $168.622M ▼ $208.941M ▼ $10.6M ▼ $198.341M ▼
Q4-2024 $1.266B ▲ $1.552B ▲ $84.085M ▲ $1.468B ▲
Q3-2024 $184.391M $232.682M $14.799M $217.883M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $22.173M ▲ $0 ▲ $0 ▲ $0 ▼ $0 ▼ $0 ▲
Q2-2025 $-13.268M ▲ $-72.302M ▼ $-386.022M ▼ $552.484M ▲ $94.16M ▲ $-71.98M ▼
Q1-2025 $-22.869M ▲ $0 $0 $0 $0 $0
Q4-2024 $-66.144M ▲ $0 $0 $0 $0 $0
Q3-2024 $-143.798M $0 $0 $0 $0 $0

Revenue by Products

Product Q3-2020Q4-2020Q2-2022Q4-2022
Grant
Grant
 $10.00M ▲$0 ▼$0 ▲$20.00M ▲
Licensing and Collaboration
Licensing and Collaboration
 $0 ▲$0 ▲$20.00M ▲$0 ▼
Supply Of Investigational Products
Supply Of Investigational Products
 $0 ▲$0 ▲$30.00M ▲$0 ▼

Five-Year Company Overview

Income Statement

Income Statement Revenue has been growing steadily over the last three years, and profits have risen even faster than sales. Margins have improved as the bank has become more efficient, with operating and net income both climbing meaningfully. This suggests better cost control and a more profitable mix of business, even though the most recent year shows slightly lower gross profitability than the prior year. Overall, the earnings trend is clearly upward, but it is coming off a relatively small base and is still tied closely to mortgage and lending conditions.

Balance Sheet

Balance Sheet The balance sheet has expanded, with total assets and cash on hand increasing each year. Equity has been edging higher, which is positive for financial resilience, but leverage has also risen compared with a few years ago, which is typical for a growing bank. Debt levels appear stable recently but higher than earlier in the period, indicating more borrowing or funding sources being used to support growth. The structure looks consistent with a regional bank that is scaling up, but it will be important to monitor how asset quality and funding costs evolve as the balance sheet continues to grow.

Cash Flow

Cash Flow Cash flow from operations was very strong in earlier years but dropped sharply to only slightly positive in the most recent period. For a bank, this kind of volatility can reflect shifts in loan growth, deposit flows, and working capital rather than core profitability, which has improved. Capital spending is minimal, so free cash flow largely mirrors operating cash flow. The picture suggests a business reinvesting heavily into loans and growth rather than one generating steady excess cash at this stage. Observers will want to see whether cash generation becomes more consistent as growth matures.

Competitive Edge

Competitive Edge Northpointe operates as a specialized, niche-focused bank rather than a generic regional lender. Its strengths include a national footprint in mortgage-related products, a strong position in warehouse lending to mortgage bankers, and a broad lineup of tailored mortgage offerings for different borrower types. The combination of a bank charter (and thus lower funding costs), a service-heavy culture, and quick decision-making supported by a flat organization gives it an edge against more rigid, larger competitors. Key risks include concentration in mortgage and housing-related activities, sensitivity to interest rate cycles, and ongoing competition from both big banks and tech-driven non-bank lenders.

Innovation and R&D

Innovation and R&D Instead of traditional R&D, Northpointe invests in in-house technology aimed at making lending faster and easier for both clients and staff. Its proprietary warehouse lending platform and its HOME point-of-sale system for retail borrowers are core examples, integrating closely with clients’ systems and simplifying the application process. The bank emphasizes practical, problem-solving tools over flashy technology, which can deepen customer relationships and improve efficiency. Looking ahead, continued digital investment, better online experiences, and potential technology-enabled products are central to its growth plans, but they also require ongoing spending and careful attention to cybersecurity and regulatory compliance.

Summary

Northpointe Bancshares is growing its revenue and earnings at a healthy pace while building out a more innovative, tech-enabled mortgage and lending franchise. The financial statements show improving profitability and a larger asset base, though operating cash flow has become more volatile as the bank leans into growth. Its competitive strengths lie in a focused niche strategy, proprietary technology, and a relationship-driven culture backed by the structural advantages of a bank charter. On the other hand, its fortunes remain tied to the mortgage and housing ecosystem and to its ability to scale technology and operations responsibly after going public. Overall, it looks like an emerging, specialized regional bank trying to leverage technology and service to punch above its weight in a competitive market.

NEWS

October 29, 2025 · 9:00 AM UTC

I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform

Read more

October 28, 2025 · 10:00 AM UTC

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB

Read more

October 23, 2025 · 10:00 AM UTC

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB

Read more

October 22, 2025 · 12:35 PM UTC

I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025

Read more

October 21, 2025 · 5:00 PM UTC

Northpointe Bancshares, Inc. Reports Third Quarter 2025 Results

Read more